Page last updated: 2024-10-30

meclofenoxate and Neuroleptic Malignant Syndrome

meclofenoxate has been researched along with Neuroleptic Malignant Syndrome in 1 studies

Meclofenoxate: An ester of DIMETHYLAMINOETHANOL and para-chlorophenoxyacetic acid.

Neuroleptic Malignant Syndrome: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Diedrich, U1
Müller, P1

Other Studies

1 other study available for meclofenoxate and Neuroleptic Malignant Syndrome

ArticleYear
[Severe late dyskinesia caused by neuroleptics in a young female. Follow-up and treatment].
    Der Nervenarzt, 1989, Volume: 60, Issue:12

    Topics: Adolescent; Carbamazepine; Clozapine; Diagnosis, Differential; Dose-Response Relationship, Drug; Dru

1989